Pharvaris Netherlands B.V. — Sponsor Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

3 Recruiting

7 Completed trials

14 Countries active

4 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase I (Other)

Phase III: 4 Phase II/III: 1 Phase II: 1 Phase I (Other): 4

Oversight events:

1 corrective measure across 1 trial

View oversight register →

100%

7 of 7 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Hereditary angioedema 6 Acquired C1 inhibitor deficiency 1

Top IMPs

DEUCRICTIBANT 5 (S)-N-(1-DEUTERO-1-(3-CHLORO-5-FLUORO-2-((2-METHYL-4-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)QUINOLIN-8-YLOXY)METHYL)PHENYL)ETHYL)-2-(DIFLUOROMETHOXY)ACETAMIDE 2

All trials

10 total

Study to Evaluate the Efficacy and Safety of Deucrictibant for Prophylactic and On-demand Treatment of Angioedema Attacks in Adults with Acq… Recruiting

2025-522051-26-00 Phase III 9 countries DEUCRICTIBANT
An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in … Recruiting

2023-505766-28-00 Phase II/III 14 countries (S)-N-(1-DEUTERO-1-(3-CHLORO-5-FLUORO-2-((2-METHYL-4-(1-METHYL-1H-1,2,4-TRIAZOL-…
CHAPTER-4 – A long term trial of deucrictibant treatment in prophylaxis against HAE attacks in adults and adolescents Recruiting

2024-516248-24-00 Phase III 11 countries DEUCRICTIBANT
CHAPTER-3 – A randomised clinical trial to assess efficacy and safety of deucrictibant treatment in prophylaxis against HAE attacks in adult… Ended

2024-516247-62-00 Phase III 10 countries DEUCRICTIBANT
A Phase I, Open-Label, Randomized, Two-Period, Cross-Over Study in Healthy Subjects to Assess the Influence of a High-Calorie, High-Fat Meal… Ended

2024-518453-41-00 Phase I (Other) 1 country
An open-label, fixed sequence drug interaction study in healthy subjects to investigate the effect of multiple doses of the gastric acid-red… Ended

2023-506305-18-01 Phase I (Other) 1 country
A Phase I, open-label, fixed sequence drug interaction study in healthy subjects to investigate the effect of a 40 mg deucrictibant tablet a… Ended

2024-514713-35-00 Phase I (Other) 1 country
A Phase 3, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adu… Ended

2023-507268-37-00 Phase III 14 countries DEUCRICTIBANT
A Phase I, open-label, randomized, two period, cross-over study in healthy subjects to assess the bioavailability of different formulations … Ended

2024-511196-15-00 Phase I (Other) 1 country
A blinded, placebo-controlled and randomized phase 2 study to test different doses of oral PHA-022121 for prophylaxis of angioedema attacks … Ended

2023-505549-18-00 Phase II 6 countries (S)-N-(1-DEUTERO-1-(3-CHLORO-5-FLUORO-2-((2-METHYL-4-(1-METHYL-1H-1,2,4-TRIAZOL-…

Showing 1–10 of 10 trials

← All sponsors A–Z